Amgen Inc. (AMGEN-T, 4332.HK) is listed on HKEX. The latest available quote update was captured at 2026-03-26 10:40:17.0.
Quote Snapshot
- Last Price: N/A
- Day Change: N/A (N/A%)
- Open: N/A
- High: N/A
- Low: N/A
- Previous Close: 1850.000 HKD
- Volume: N/A
- Market Cap: 1,128.38 B
- P/E Ratio: N/A
- Dividend Yield: N/A
- Board Lot: 10
- ISIN: US0311621009
- Industry: N/A
Company Overview
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.